Get the Stockscreener App
0.1201
4.23%
-0.0053
After Hours:
.12
-0.0001
-0.08%
Petros Pharmaceuticals Inc stock is traded at $0.1201, with a volume of 56.55M.
It is down -4.23% in the last 24 hours and down -90.73% over the past month.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.
See More
Previous Close:
$0.1254
Open:
$0.1371
24h Volume:
56.55M
Relative Volume:
14.17
Market Cap:
$533.05K
Revenue:
$4.02M
Net Income/Loss:
$-4.73M
P/E Ratio:
-0.0285
EPS:
-4.21
Net Cash Flow:
$-5.85M
1W Performance:
-51.77%
1M Performance:
-90.73%
6M Performance:
-98.49%
1Y Performance:
-99.25%
1-Day Range:
$0.101
$0.21
1-Week Range:
$0.101
$0.2377
52-Week Range:
$0.101
$18.00
Petros Pharmaceuticals Inc Stock (PTPI) Company Profile
Name
Petros Pharmaceuticals Inc
Sector
Phone
973-242-0005
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Compare PTPI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTPI
Petros Pharmaceuticals Inc
|
0.1201 | 533.05K | 4.02M | -4.73M | -5.85M | -4.21 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Petros Pharmaceuticals Inc Stock (PTPI) Latest News
Petros Pharmaceuticals enhances AI for Rx-to-OTC switch platform By Investing.com - Investing.com India
Petros Pharmaceuticals enhances AI for Rx-to-OTC switch platform - Investing.com
Petros Pharmaceuticals (PTPI) Boosts AI Platform with Advanced F - GuruFocus
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform - ACCESS Newswire
Petros Pharma Upgrades AI Platform Following Trump Order to Expand OTC Drug Access - Stock Titan
Petros Pharmaceuticals Announces Reverse Stock Split By Investing.com - Investing.com Australia
Petros Pharmaceuticals Announces Reverse Stock Split - Investing.com
Petros Pharma Stock Plunges To Record Low On 1-For-25 Reverse Split, But Retail Optimism Lingers - Asianet Newsable
Petros Pharmaceuticals (PTPI) Aims to Transform with Innovative Healthcare Platform | PTPI Stock News - GuruFocus
Petros Pharmaceuticals pivots to smart healthcare tech By Investing.com - Investing.com India
Petros Pharmaceuticals pivots to smart healthcare tech - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Trump Healthcare Initiative Drives Petros Pharma's $38B AI Platform Innovation for OTC Drug Approvals - Stock Titan
Petros Pharmaceuticals (PTPI) Aligns with Regulatory Climate Und - GuruFocus
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider - ACCESS Newswire
You might want to take a look at Petros Pharmaceuticals Inc (PTPI) now - Sete News
Petros Pharmaceuticals gears up for Rx-to-OTC switch platform - Investing.com
Petros Pharmaceuticals to effect 1-for-25 reverse stock split - TipRanks
PTPI Announces Reverse Stock Split at 1-for-25 Ratio | PTPI Stoc - GuruFocus
US Stocks Mixed; Coca-Cola Posts Upbeat Earnings - Benzinga
Petros Pharmaceuticals gears up for Rx-to-OTC switch platform By Investing.com - Investing.com UK
Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan
Petros Pharmaceuticals (PTPI) Stock Soars 45% Over the Week - GuruFocus
Petros Pharmaceuticals (PTPI) Enhances Rx-to-OTC Platform with A - GuruFocus
PTPI’s Stock Market Adventure: -79.26% YTD Growth Amidst Volatility - investchronicle.com
PTPI Stock Plummets, But Premarket Hints at a Possible Rebound - Own Snap
A stock that deserves closer examination: Petros Pharmaceuticals Inc (PTPI) - uspostnews.com
Petros Pharmaceuticals Inc (PTPI) can make a big difference with a little luck - Sete News
Petros Pharmaceuticals stock hits 52-week low at $0.04 By Investing.com - Investing.com South Africa
Ratio Analysis: Unpacking Petros Pharmaceuticals Inc (PTPI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Petros Pharmaceuticals stock hits 52-week low at $0.04 - Investing.com
Investing in Petros Pharmaceuticals Inc (PTPI) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
Are Petros Pharmaceuticals Inc (PTPI) shares a good deal now? - uspostnews.com
Petros Pharmaceuticals faces delisting, stockholders approve equity changes - Investing.com Australia
Petros Pharmaceuticals faces delisting, stockholders approve equity changes By Investing.com - Investing.com Canada
Petros Pharmaceuticals Approves Key Amendments to Incorporation - TipRanks
Petros Pharmaceuticals appoints new auditor for 2025 By Investing.com - Investing.com South Africa
Petros Pharmaceuticals appoints new auditor for 2025 - Investing.com
PTPI stock plunges to 52-week low of $0.05 amid market challenges - Investing.com Australia
PTPI stock plunges to 52-week low of $0.05 amid market challenges By Investing.com - Investing.com South Africa
Petros Pharmaceuticals modifies terms with investors - MSN
A closer look at Petros Pharmaceuticals Inc (PTPI)’s stock price trends - uspostnews.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Petros Pharmaceuticals, Inc. SEC 10-K Report - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Petros Pharmaceuticals Inc Stock (PTPI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):